Hoffmann, David
Mereiter, Stefan https://orcid.org/0000-0002-4832-3090
Jin Oh, Yoo https://orcid.org/0000-0002-9636-3329
Monteil, Vanessa https://orcid.org/0000-0002-2652-5695
Elder, Elizabeth https://orcid.org/0000-0003-1615-2642
Zhu, Rong
Canena, Daniel
Hain, Lisa
Laurent, Elisabeth https://orcid.org/0000-0002-5234-5524
Grünwald‐Gruber, Clemens
Klausberger, Miriam https://orcid.org/0000-0001-8409-454X
Jonsson, Gustav https://orcid.org/0000-0001-6692-8395
Kellner, Max J
Novatchkova, Maria
Ticevic, Melita
Chabloz, Antoine
Wirnsberger, Gerald
Hagelkruys, Astrid https://orcid.org/0000-0003-3015-4038
Altmann, Friedrich
Mach, Lukas https://orcid.org/0000-0001-9013-5408
Stadlmann, Johannes
Oostenbrink, Chris
Mirazimi, Ali https://orcid.org/0000-0003-2371-6055
Hinterdorfer, Peter https://orcid.org/0000-0003-2583-1305
Penninger, Josef M https://orcid.org/0000-0002-8194-3777
Funding for this research was provided by:
T. von Zastrow Foundation (Z 271‐B19)
Austrian Academy of Sciences (101005026)
Canada 150 Research Chairs Program (F18‐01336)
Gouvernement du Canada|Canadian Institutes of Health Research (F20‐02343)
Gouvernement du Canada|Canadian Institutes of Health Research (F20‐02015)
European Union's Horizon 2020 (841319)
Austrian Science Fund (V584)
Austrian Science Fund (I3173)
Austrian Science Fund (P31599)
Vienna Science and Technology Fund (LS19‐029)
Vienna Science and Technology Fund (COV20‐015)
ÖAW Fellowship (STIP13202002)
European Union's Horizon 2020 (721874)
Innovative Medicines Initiative 2 (101005026)
Article History
Received: 31 March 2021
Revised: 19 July 2021
Accepted: 28 July 2021
First Online: 23 August 2021
Change Date: 4 October 2021
Change Type: Update
Change Details: The copyright line of this article was changed on 4 October 2021 after original online publication.
Conflict of interest
: A patent is being prepared to use CLEC4G as potential therapy for COVID‐19. J.M.P. is shareholder and board member of Apeiron Biologics that is developing soluble ACE2 for COVID‐19 therapy.